Unlock this StockReport nowClick to Unlock

Zealand Pharma A/S Share Price

ZEAL DKK138.2 -3.8  -2.7%
3:59pm
StockRank

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
Margin of Safety (beta)
Screens Passed 3 / 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 TTM 2019E 2020E CAGR / Avg
Revenue DKKm
Operating Profit DKKm
Net Profit DKKm
EPS Reported DKK
EPS Normalised DKK
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps DKK
Capex ps DKK
Free Cashflow ps DKK
Dividends
Dividend ps DKK
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc DKKm
Working Capital DKKm
Net Fixed Assets DKKm
Net Debt DKKm
Book Value DKKm
Average Shares m
Book Value ps DKK +21.1%

FINANCIAL BRIEF: For the six months ended 30 June 2019, Zealand Pharma Aktieselskabet revenues decreased 20% to DKR19.9M. Net loss increased 27% to DKR264.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development expenses increase of 23% to DKR256.9M (expense), Administrative expenses increase from DKR16.3M to DKR35.2M (expense). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
A+
A+
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 30th Jun '19) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2019
31st Dec 2020

Price Target: DKK168.3
(+18.51% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (DKK) (DKK) (DKK) (DKK) (DKK) (DKK)
Consensus Estimate
1m Change
3m Change
8 brokers Broker Consensus Trend
Broker Recommendations for Zealand Pharma A/S
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 1 5 3

Named Brokers and Analysts
Needham & Company Inc. Alan Carr , Jefferies Peter Welford , Morgan Stanley , Goldman Sachs Research Graig Suvannavejh , Danske Markets Martin Parkhøi Mattias Häggblom Thomas Bowers , Kempen & Co Suzanne Van Voorthuizen , Nordea Markets Michael Novod , Handelsbanken Capital Markets Peter Sehested , ODDO BHF Oussema Denguir , Bryan Garnier Eric Le Berrigaud , Guggenheim Securities LLC Tony Butler ,

Profile Summary

Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area offers ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment. Furthermore, the Company collaborates with a number of partners, such as Sanofi, Helsinn, Boehringer Ingelheim, Abbvie and Eli Lilly.

Directors: Alf Nicklasson (CHM) 64, Emmanuel Dulac (CEO) 49, Kirsten Drejer (VCH) 63, Ivan Moeller (COO) 47, Andrew Parker (EVP) 54, Adam Steensberg (EVP) 45, Marino Garcia (SVP) 53, Hanne Heidenheim Bak (DRC) 66, Jens Stenvang (DRC) 65, Jeffrey Berkowitz (IND) 53, Bernadette Connaughton (IND) 60, Leonard Kruimer (IND) 61,

No. of Employees: 172 No. of Shareholders: 16,204


Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated April 1, 1997
Public Since November 1, 2010
Shares in Issue 31,750,567
Free Float 31.8m (100.0%)
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange OMX Nordic Exchange - Copenhagen
Eligible for an ISA? a SIPP?

ZEAL Share Price Performance ZEAL Share Price Quote
DKK138.2
-3.8  -2.7%
Traded 3:59pm · Minimum 15 min delayed · NMS:

Latest ZEAL News Announcements (delayed)

Upcoming ZEAL Events

Recent ↓
Thursday 21st March, 2019
Zealand Pharma A/S - Special Call
Tuesday 18th September, 2018
Zealand Pharma A/S - Special Call
Friday 7th September, 2018
Zealand Pharma A/S - Special Call
Friday 18th May, 2018 (estimate)
Q1 2018 Zealand Pharma A/S Earnings Release
Tuesday 8th May, 2018
Zealand Pharma A/S at Deutsche Bank Health Care Conference
Tuesday 27th March, 2018
Zealand Pharma A/S at Needham Healthcare Conference
Monday 12th March, 2018
Zealand Pharma A/S at Cowen Health care Conference
Wednesday 7th March, 2018
Q4 2017 Zealand Pharma A/S Earnings Release
Tuesday 27th February, 2018
Zealand Pharma A/S at Credit Suisse Global Healthcare Conference
Thursday 15th February, 2018
Zealand Pharma A/S at Leerink Partners Global Healthcare Conference
Wednesday 8th November, 2017
Q3 2017 Zealand Pharma A/S Earnings Release
Thursday 2nd November, 2017
Q3 2017 Zealand Pharma A/S Earnings Release
Thursday 24th August, 2017
Q2 2017 Zealand Pharma A/S Earnings Release
Wednesday 9th August, 2017
Zealand Pharma A/S Secondary Public Offering Pricing
Wednesday 17th May, 2017
Q1 2017 Zealand Pharma A/S Earnings Release
Wednesday 15th March, 2017
Q4 2016 Zealand Pharma A/S Earnings Release
Wednesday 8th February, 2017
Q4 2016 Zealand Pharma A/S Earnings Release
Wednesday 9th November, 2016
Q3 2016 Zealand Pharma A/S Earnings Call
Wednesday 9th November, 2016
Q3 2016 Zealand Pharma A/S Earnings Release
Friday 30th September, 2016
Zealand Pharma A/S Secondary Public Offering Pricing


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.


Should you buy ZEAL

Access ZEAL Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis